Literature DB >> 24900792

FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures.

Tobias Klein1, Julie Tucker1, Geoffrey A Holdgate1, Richard A Norman1, Alexander L Breeze1.   

Abstract

The binding of a ligand to its target protein is often accompanied by conformational changes of both the protein and the ligand. This is of particular interest, since structural rearrangements of the macromolecular target and the ligand influence the free energy change upon complex formation. In this study, we use X-ray crystallography, isothermal titration calorimetry, and surface-plasmon resonance biosensor analysis to investigate the binding of pyrazolylaminopyrimidine inhibitors to FGFR1 tyrosine kinase, an important anticancer target. Our results highlight that structurally close analogs of this inhibitor series interact with FGFR1 with different binding modes, which are a consequence of conformational changes in both the protein and the ligand as well as the bound water network. Together with the collected kinetic and thermodynamic data, we use the protein-ligand crystal structure information to rationalize the observed inhibitory potencies on a molecular level.

Entities:  

Keywords:  Receptor tyrosine kinase; X-ray crystallography; induced fit; isothermal titration calorimetry; protein−ligand interactions; surface plasmon resonance

Year:  2013        PMID: 24900792      PMCID: PMC4027782          DOI: 10.1021/ml4004205

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

1.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.

Authors:  M Mohammadi; G McMahon; L Sun; C Tang; P Hirth; B K Yeh; S R Hubbard; J Schlessinger
Journal:  Science       Date:  1997-05-09       Impact factor: 47.728

2.  Statistical analysis of the effects of common chemical substituents on ligand potency.

Authors:  Philip J Hajduk; Daryl R Sauer
Journal:  J Med Chem       Date:  2008-01-04       Impact factor: 7.446

3.  Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.

Authors:  Richard A Norman; Anne-Kathrin Schott; David M Andrews; Jason Breed; Kevin M Foote; Andrew P Garner; Derek Ogg; Jonathon P Orme; Jennifer H Pink; Karen Roberts; David A Rudge; Andrew P Thomas; Andrew G Leach
Journal:  J Med Chem       Date:  2012-05-21       Impact factor: 7.446

4.  Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.

Authors:  Jeffrey R Simard; Matthäus Getlik; Christian Grütter; Ralf Schneider; Sabine Wulfert; Daniel Rauh
Journal:  J Am Chem Soc       Date:  2010-03-31       Impact factor: 15.419

Review 5.  Protein kinase biochemistry and drug discovery.

Authors:  Phillip A Schwartz; Brion W Murray
Journal:  Bioorg Chem       Date:  2011-08-03       Impact factor: 5.275

6.  The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.

Authors:  Sandra W Cowan-Jacob; Gabriele Fendrich; Paul W Manley; Wolfgang Jahnke; Doriano Fabbro; Janis Liebetanz; Thomas Meyer
Journal:  Structure       Date:  2005-06       Impact factor: 5.006

7.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.

Authors:  Magdalena Koziczak; Thomas Holbro; Nancy E Hynes
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

10.  Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Authors:  Bhushan Nagar; Oliver Hantschel; Matthew A Young; Klaus Scheffzek; Darren Veach; William Bornmann; Bayard Clarkson; Giulio Superti-Furga; John Kuriyan
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

View more
  3 in total

1.  Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.

Authors:  Christal D Sohl; Molly R Ryan; BeiBei Luo; Kathleen M Frey; Karen S Anderson
Journal:  ACS Chem Biol       Date:  2015-02-24       Impact factor: 5.100

2.  Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase.

Authors:  Tobias Klein; Navratna Vajpai; Jonathan J Phillips; Gareth Davies; Geoffrey A Holdgate; Chris Phillips; Julie A Tucker; Richard A Norman; Andrew D Scott; Daniel R Higazi; David Lowe; Gary S Thompson; Alexander L Breeze
Journal:  Nat Commun       Date:  2015-07-23       Impact factor: 14.919

3.  ITC-derived binding affinity may be biased due to titrant (nano)-aggregation. Binding of halogenated benzotriazoles to the catalytic domain of human protein kinase CK2.

Authors:  Maria Winiewska; Ewa Bugajska; Jarosław Poznański
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.